Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression

Circ Res. 2002 Jun 14;90(11):1222-30. doi: 10.1161/01.res.0000021127.83364.7d.

Abstract

Insulin-like growth factor (IGF)-1 and the type I IGF-1 receptor are important regulators of vascular function that may contribute to cardiovascular disease. We hypothesized that IGF-1 causes endothelial cell dysfunction and expression of neutrophil and monocyte adhesion molecules by enhancing pro-inflammatory cytokine signal transduction. Long-term IGF-1 treatment of endothelial cells potentiated c-Jun and nuclear factor NF-kappaB activation by tumor necrosis factor (TNF)-alpha and enhanced TNF-alpha-mediated adhesion molecule expression. In response to IGF-1 treatment, the expression of kinases in the c-Jun/c-Jun NH(2)-terminal kinase signaling pathway (MEKK1, MEK4, and JNK1/2) was unchanged, but expressions of insulin receptor substrate-1 and Grb2-associated binder-1 (Gab1) were significantly decreased. Because Gab1 is involved in both c-Jun and NF-kappaB activation by TNF-alpha, we focused on Gab1-dependent signaling. Gab1 inhibited c-Jun and NF-kappaB transcriptional activation by TNF-alpha. Interestingly, Gab1 inhibited c-Jun transcriptional activity induced by MEKK3 but not MEKK1 and MEK4. Gab1 associated with MEKK3, and a catalytically inactive form of MEKK3 inhibited TNF-alpha-induced c-Jun and NF-kappaB transcriptional activation, suggesting a critical role for Gab1 and MEKK3 in TNF-alpha signaling. These data demonstrate that Gab1 and MEKK3 play important roles in endothelial cell inflammation via regulating the activation of c-Jun and NF-kappaB. Furthermore, the IGF-1-mediated downregulation of Gab1 expression represents a novel mechanism to promote vascular inflammation and atherosclerosis.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Animals
  • Cattle
  • Cell Adhesion / drug effects
  • Cell Adhesion Molecules / biosynthesis
  • Cell Line
  • Cells, Cultured
  • Drug Synergism
  • E-Selectin / biosynthesis
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Humans
  • Inflammation Mediators / administration & dosage
  • Insulin-Like Growth Factor I / pharmacology*
  • Intercellular Adhesion Molecule-1 / biosynthesis
  • MAP Kinase Kinase Kinase 3
  • MAP Kinase Kinase Kinases / genetics
  • MAP Kinase Kinase Kinases / physiology
  • Monocytes / cytology
  • Monocytes / drug effects
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Phosphoproteins / genetics
  • Phosphoproteins / physiology
  • Plasmids / genetics
  • Proto-Oncogene Proteins c-jun / genetics
  • Proto-Oncogene Proteins c-jun / metabolism
  • Time Factors
  • Transcriptional Activation / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Vascular Cell Adhesion Molecule-1 / biosynthesis

Substances

  • Adaptor Proteins, Signal Transducing
  • Cell Adhesion Molecules
  • E-Selectin
  • GAB1 protein, human
  • Inflammation Mediators
  • NF-kappa B
  • Phosphoproteins
  • Proto-Oncogene Proteins c-jun
  • Tumor Necrosis Factor-alpha
  • Vascular Cell Adhesion Molecule-1
  • Intercellular Adhesion Molecule-1
  • Insulin-Like Growth Factor I
  • MAP Kinase Kinase Kinase 3
  • MAP Kinase Kinase Kinases
  • MAP3K3 protein, human